Barclays maintains Ultragenyx Pharmaceutical at Overweight, lowers price target to $32 from $35

Barclays kept its Overweight rating on Ultragenyx Pharmaceutical but reduced its price target from $35 to $32, citing an 8.6% decrease. The new target suggests an 86.5% upside from the Nov 4 close of $17.16. Recent analyst price targets for the company range from $17 to $34.

Original reporting
Published Nov 5, 2026, 7:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 7:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Barclays maintains Ultragenyx Pharmaceutical at Overweight, lowers price target to $32 from $35 — source image
Decision brief

The 30-second read

Med
01

Why it matters

A lower price target may trigger short‑term selling and could influence other analysts to follow suit.

02

Market read

Analyst target revision is the primary new information, offering modest trading relevance.

03

What to watch

Potential pipeline milestones or partnership announcements not covered in the article.

Relevance 5/10Novelty 5/10Timing: today

Background

Barclays' analyst note updates ULTX's valuation based on recent data, but the article provides no additional company developments.

Market effects

May affect other rare‑disease biotech stocks as analysts reassess sector valuations.

Limited to US biotech market.

Low

Counterpoint

The target cut could be overly cautious if upcoming trial data exceeds expectations.

Key entities

  • Barclays

    Equity research firm issuing the target revision.

  • Ultragenyx Pharmaceutical

    Biotech firm focused on rare diseases.

Related articles

$RAREMed

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy

Ultragenyx Pharmaceutical Inc (RARE) discontinued two gene therapy programs (GTX-102 and UX701) due to efficacy and trial advancement issues. The company is restructuring, cutting 20% of its workforce. The future of setrusumab for osteogenesis imperfecta is uncertain pending FDA discussions. R&D spending for 2027 is guided at less than $350 million, with a focus on commercial products. The company faces potential competition in the Sanfilippo syndrome type A market.

$RAREHighAI 8/10

Ultragenyx (RARE) Q3 2026 Earnings Call Transcript

Ultragenyx (RARE) reported Q3 2026 earnings, highlighting FDA approvals for GENGLYCOS and FAYUVI, two new gene therapies. The company also announced setbacks in clinical trials for GTX-102 and UX701, leading to program terminations and workforce reductions. Revenue guidance for 2026 was reaffirmed at $730M-$760M, with profitability expected in 2027. The company aims to reduce expenses by 50% by 2027.